Institute for Fertility Preservation and Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, Valhalla, NY 10595, USA.
J Assist Reprod Genet. 2011 Jul;28(7):651-6. doi: 10.1007/s10815-011-9567-z. Epub 2011 May 4.
To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC).
The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment.
AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p = 0.001).
AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.
基于观察到的抗苗勒管激素（AMH）水平和窦卵泡计数（AFC），预测接受来曲唑和促卵泡激素刺激进行生育保存的乳腺癌患者的胚胎/卵母细胞冷冻保存周期（ECC）结局。
对 41 名接受辅助治疗前的乳腺癌女性进行回顾性分析，研究 AMH 和 AFC 与 ECC 结局之间的相关性。
与年龄、FSH 和抑制素 B 相比，AMH 和 AFC 与卵母细胞总数和成熟卵母细胞数的相关性更强。通过获得的成熟卵母细胞数量评估受试者，创建 AMH 水平的截断值，确定 1.2ng/mL 为潜在值。18 名 AMH 水平≤1.2ng/mL 的患者中，有 7 名反应不佳，而 23 名 AMH 水平>1.2ng/mL 的患者中无一例反应不佳，（p=0.001）。
在乳腺癌患者中，AMH 是 ECC 结局最可靠的血清标志物，与 AFC 作为生物物理标志物一起。当 AMH 水平≤1.2ng/mL 时，低反应的可能性非常高。
